Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.

Authors:
Xiang S; Lu X.

Journal:
Acta Pharm Sin B

Publication Year: 2023

DOI:
10.1016/j.apsb.2023.11.010

PMCID:
PMC10840435

PMID:
38322338

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Acta Pharm Sin B

Abbreviation: Acta Pharm Sin B

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
ACAT1 deficiency in myeloid cells promotes glioblastoma progression by enhancing the accumulation o…
Wang M; Wang W; You S and 6 more (2023) - Transparency Score: 3/6
Acid-switchable nanoparticles induce self-adaptive aggregation for enhancing antitumor immunity of …
Sun X; Xu X; Wang J and 8 more (2023) - Transparency Score: 3/6
Activation of insulin-like growth factor-1 receptor (IGF-1R) promotes growth of colorectal cancer t…
Xie Q; Chu Y; Yuan W and 7 more (2023) - Transparency Score: 3/6
Activation of PXR causes drug interactions with Paxlovid in transgenic mice.
Lei S; Guo A; Lu J and 4 more (2023) - Transparency Score: 3/6
Adiponectin restores the obesity-induced impaired immunomodulatory function of mesenchymal stromal …
Pham DV; Nguyen TK; Nguyen BL and 4 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest The authors have no conflicts of interest to declare."

Evidence found in paper:

"We gratefully acknowledge the financial support from the 10.13039/501100001809National Natural Science Foundation of China (82273763), the 10.13039/501100003453Natural Science Foundation of Guangdong Province (2022A1515011939, China), the Opening Project of 10.13039/100013262State Key Laboratory of Respiratory Disease (SKLRD-OP-202313, China), the Opening Project of Guangdong Provincial Key Laboratory of New Drug Design and Evaluation (2020B1212060034, China) and Wang Kuancheng Young Scholar of 10.13039/501100004024Jinan University."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025